Adaptive Biotechnologies Q2 revenue $38.5M, +83% YoY; raises FY2021 guidance to $148M-$155M

Adaptive Biotechnologies Corp

2022-Q2 EPS reported -$0.64 revenue$76,947,000

Revenue $38.5M (+83% YoY); sequencing revenue $18.6M (+132%), development revenue $20.0M (+53%).
Net loss $49.3M vs $33.5M YoY; adjusted EBITDA loss $35.6M vs $28.5M.
FY2021 revenue guidance raised to $148M-$155M (prior $145M-$155M).
clonoSEQ volume +75% YoY; signed agreements with Vaccibody and Moderna for T-cell data and COVID vaccine T-cell response measurement.
Cash and marketable securities $689.5M as of June 30, 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.